

## CHEMIPHAR UNDERWRITES THIRD-PARTY ALLOCATION OF SHARES BY AI DRUG DISCOVERY VENTURE MOLCURE, COMMENCES NEGOTIATIONS TOWARD BUSINESS ALLIANCE

Nippon Chemiphar Co., Ltd.  
(TSE: 4539)  
November 28, 2018

Nippon Chemiphar Co., Ltd. (Hereinafter “Chemiphar”), announce today that it has underwritten a portion of a third-party allocation of shares by MOLCURE Inc. (hereinafter “MOLCURE”), and signed a memorandum agreeing to commence negotiations toward a business alliance between both companies.

MOLCURE is a successful AI drug discovery business venture that utilizes AI mainly to design pharmaceuticals targeting antibodies and provides services to pharmaceutical companies. Chemiphar aims to develop groundbreaking new drugs for patients suffering from diseases for which no adequate therapeutic drugs are available. To continue creating promising drug candidates going forward, Chemiphar believes in the indispensable necessity of incorporating technological innovations and prominent digital technologies to innovate the drug discovery process itself. Chemiphar strongly endorses MOLCURE’s business model and is the first healthcare-related company to acquire a stake in MOLCURE.

In addition, Chemiphar and MOLCURE have agreed to commence negotiations on a business alliance intended to create and commercialize innovative pharmaceuticals by combining MOLCURE technologies with Chemiphar’s drug discovery platform. This alliance will not affect in any way relationships with other business partners with whom Chemiphar and MOLCURE collaborate.

### Outline of MOLCURE

Company Name:	MOLCURE Inc.
CEO:	Ryu Ogawa
Head office:	5-5-15 Kitashinagawa Shinagawa-ku, Tokyo, Japan
Established:	May 1, 2013
URL:	<a href="http://molcure.com/">http://molcure.com/</a>

### For further information contact:

Public Relations Department, Nippon Chemiphar Co., Ltd.

E-mail: [ir@chemiphar.co.jp](mailto:ir@chemiphar.co.jp)